dapagliflozin viatris
viatris limited - dapagliflozīns - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
eucreas
novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
zomarist
novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.
eltrombopag olainfarm 12,5 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 12,5 mg
eltrombopag olainfarm 25 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 25 mg
eltrombopag olainfarm 50 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 50 mg
eltrombopag olainfarm 75 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 75 mg
dapagliflozin polpharma 5 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 5 mg
dapagliflozin polpharma 10 mg apvalkotās tabletes
zaklady farmaceutyczne polpharma s.a., poland - dapagliflozīns - apvalkotā tablete - 10 mg
enyglid
krka, d.d., novo mesto - repaglinide - cukura diabēts, 2. tips - cukura diabēts - repaglinide tiek norādīta pacientiem ar 2. tipa cukura diabētu (non-insulīns - dependent cukura diabēts (niddm)) kuru hyperglycaemia vairs tiek regulēts apmierinoši, diētu, svara samazināšanu un vingrošanu. repaglinīds ir indicēts arī kombinācijā ar metformīnu 2. tipa cukura diabēta pacientiem, kurus pietiekamā mērā nekontrolē tikai metformīns. Ārstēšana jāuzsāk, kā palīglīdzekli, lai diētu un vingrinājumiem, lai samazinātu asins glikozes attiecībā uz ēdienu,.